НовостиBenzingaWedbush Maintains Outperform on Climb Bio, Raises Price Target to $27 Wedbush Maintains Outperform on Climb Bio, Raises Price Target to $27 Benzinga 2026.11.06 16:54 (GMT+0) Открыть на Benzinga Другие новости